Comparing the current results to its competitors, Microbot Medical Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Microbot Medical Inc 's competitors' average revenue growth of 19.37 %, achieved in the same quarter.
Microbot Medical Inc 's Comment on Competition and Industry Peers
The LIBERTY® Endovascular Robotic Surgical System competes primarily with the CorPath GRX vascular robotics system by Corindus Vascular Robotics, a Siemens Healthineers company, which holds FDA approval and CE marking for various vascular procedures. Another competitor is the R-One+ system by Robocath, which is CE marked and approved by the NMPA and in South Africa for percutaneous coronary intervention (PCI) only. Additional competitors in development include LN Robotics, approved in Korea for coronary interventions; Nanoflex Robotics; UAB Inovatyvi medicina; and Endoways. These competing systems face challenges such as limited maneuverability, the requirement for multiple costly tools, large operating space needs, complex setup processes, and high capital expenditures. Some competitors benefit from greater resources, established relationships, and long-term contracts, which may influence Microbot's competitive position.
July 8, 2024
Microbot Medical, a leading medical robotics company, has achieved a significant milestone by enrolling the first patient in its pivotal human clinical trial. This groundbreaking trial, taking place at Brigham and Women s Hospital, marks a crucial step forward in the development of Microbot s innovative medical technologies. In this article, we will summarize the key facts surrounding this achievement, draw upon the relevant information from the provided articles, and provide an overview of the current progress made by Microbot Medical.1. The Clinical Trial:Microbot Medical s pivotal clinical trial aims to investigate the safety and efficacy of their advanced medical robotics platform. Building upon their e...
July 3, 2024
: Microbot Medical, a frontrunner in the field of medical technology, has expanded its pivotal human clinical trial to Baptist Hospital of Miami following FDA approval. This expansion marks a critical step in the company s mission to innovate and enhance patient care through advanced robotic technologies. In a significant leap towards transforming medical procedures, Microbot Medical has secured FDA approval to commence its pivotal human clinical trial. The company’s focus on developing advanced micro-robotic systems aims to revolutionize minimally invasive surgeries. This article delves into the details of this clinical trial and assesses its potential impact on Microbot Medical s growth and the broader ...
June 20, 2024
Microbot Medical Inc., a leading biotechnology firm specializing in developing micro-robotic medical technologies, has recently announced a significant partnership with Brigham and Women s Hospital (BWH) for the commencement of its pivotal human clinical trial. This collaboration marks a notable milestone following the Food and Drug Administration s (FDA) approval to initiate the trial. An official site initiation has taken place, signifying the preparedness for advancing patient enrollment. FDA Approval and Site Initiation Microbot Medical received the green light from the FDA to commence its clinical trial, a critical step that underscores the potential of its innovative technologies in improving patient o...
April 15, 2024
Microbot Medical, a leading medical robotics company, has assured investors and stakeholders that all regulatory, clinical, operational, and pre-commercial activities are continuing as planned despite the ongoing situation in Israel. In a recent statement, the company addressed concerns over the impact of geopolitical events on its operations, emphasizing its resilience and commitment to delivering innovative healthcare solutions.The situation in Israel, characterized by escalated conflict and instability, has raised questions about the potential disruptions to Microbot Medical s operations. However, the company remains steadfast in its determination to navigate through the challenges and maintain its growth...
January 18, 2024
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical StudyMicrobot Medical, a leading medical robotics company, continues to make significant strides in the development of its groundbreaking technology. Following the recent positive results of its pivotal Good Laboratory Practice (GLP) pre-clinical study, the company is now expanding its US clinical infrastructure to support the upcoming submission of its Investigational Device Exemption (IDE) for its first in human clinical study. This exciting development brings Microbot Medical one step closer to revolutionizing the field of healthcare.In order to effectively facilitate its f...
December 28, 2023
Microbot Medical, a trailblazer in the field of nano-robotic medical devices, has achieved landmark success with the completion of its latest good laboratory practice (GLP) pivotal pre-clinical study. This groundbreaking study achieved all predefined objectives, outcomes that will, in no uncertain terms, be supporting the company’s Investigational Device Exemption (IDE) submission to the Food and Drug Administration (FDA). This enhances not only Microbot Medical s profile in the realm of innovative health solutions but also injects renewed optimism into medicine s technological future.Whilst human clinical studies are often rightly perceived as the most critical facet of medicinal progress, comprehensive a...
Myomo Inc's business model revolves around the development and commercialization of advanced medical devices, specifically myoelectric orthotics for individuals with neuromuscular disorders.
Pavmed Inc is a medical device company that focuses on developing and commercializing innovative products for various medical fields. The company's business model revolves around identifying unmet medical needs, acquiring proprietary rights to potential products, and advancing them through development stages to obtain regulatory approvals and market them.
Sanuwave Health Inc operates through a business model centered on developing and commercializing innovative regenerative medicine technologies. The company focuses on creating noninvasive, nonthermal, and durable ultrasound therapeutic devices to treat various medical conditions. Sanuwave Health Inc primarily generates revenue by selling its products and securing licensing agreements with healthcare providers and distributors.
Vycor Medical Inc has a business model focused on developing and commercializing innovative medical devices and technologies in the healthcare industry.
Irhythm Technologies Inc is a healthcare company that focuses on providing remote cardiac monitoring solutions. Their business model revolves around offering wearable devices that continuously monitor heart rhythms, combined with cloud-based data analysis. They generate revenue by selling and leasing their devices, as well as providing analysis services and data reports to healthcare professionals.
Sources:
Microbot Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Microbot Medical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
